Positron emission tomography molecular imaging for drug development.
暂无分享,去创建一个
Paul M. Matthews | Roger N. Gunn | Jan Passchier | Eugenii A. Rabiner | P. Matthews | J. Passchier | E. Rabiner | R. Gunn
[1] Nicholas J Long,et al. Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. , 2008, Angewandte Chemie.
[2] Wolfgang Löscher,et al. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases , 2005, Progress in Neurobiology.
[3] P. Matthews,et al. Advances in the molecular imaging of multiple sclerosis , 2009, Expert review of clinical immunology.
[4] Bengt Långström,et al. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development , 2003, European Journal of Clinical Pharmacology.
[5] R Gomeni,et al. Adaptive‐Optimal Design in PET Occupancy Studies , 2010, Clinical pharmacology and therapeutics.
[6] Oscar Ces,et al. Degradative transport of cationic amphiphilic drugs across phospholipid bilayers , 2006, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.
[7] Alan A. Wilson,et al. Evaluation of 11C-GSK189254 as a Novel Radioligand for the H3 Receptor in Humans Using PET , 2010, Journal of Nuclear Medicine.
[8] W. Heiss,et al. The potential of PET/MR for brain imaging , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[9] M Slifstein,et al. Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. , 2001, Nuclear medicine and biology.
[10] Joost Bart,et al. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. , 2004, Current pharmaceutical design.
[11] Vijay K Gombar,et al. Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. , 2004, Journal of pharmaceutical sciences.
[12] E. Rabiner,et al. In Vivo Binding of Antipsychotics to D3 and D2 Receptors: A PET Study in Baboons with [11C]-(+)-PHNO , 2011, Neuropsychopharmacology.
[13] Robert B. Innis,et al. Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands , 2011, The Journal of Nuclear Medicine.
[14] F. Turkheimer,et al. A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. , 2009, Cancer research.
[15] S. Gambhir,et al. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] Aiman Abrahim,et al. A Combined Accelerator Mass Spectrometry-Positron Emission Tomography Human Microdose Study with 14C- and 11C-Labelled Verapamil , 2011, Clinical pharmacokinetics.
[17] S. Osman,et al. Metabolic activation of temozolomide measured in vivo using positron emission tomography. , 2003, Cancer research.
[18] S. Kitson,et al. Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology , 2009 .
[19] M. Hamon,et al. Selective in vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse. , 1994, European journal of pharmacology.
[20] Phil Jeffrey,et al. Improving the in Vitro Prediction of in Vivo Central Nervous System Penetration: Integrating Permeability, P-glycoprotein Efflux, and Free Fractions in Blood and Brain , 2006, Journal of Pharmacology and Experimental Therapeutics.
[21] J O Rinne,et al. Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[22] A Malizia,et al. First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635. , 1995, European journal of pharmacology.
[23] A. Bogni,et al. A new, convenient method for the preparation of 4-[18F]fluorobenzyl halides. , 2000, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[24] Roger N Gunn,et al. An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[25] G. V. van Dongen,et al. Immuno-positron emission tomography: shedding light on clinical antibody therapy. , 2010, Cancer biotherapy & radiopharmaceuticals.
[26] Nick C Fox,et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.
[27] E T Bullmore,et al. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans , 2011, Molecular Psychiatry.
[28] Thomas E. Nichols,et al. A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.
[29] S. Gambhir,et al. Quantitative PET Imaging of Tumor Integrin αvβ3 Expression with 18F-FRGD2 , 2006 .
[30] Stefano Zamuner,et al. Prediction of Repeat-Dose Occupancy from Single-Dose Data: Characterisation of the Relationship between Plasma Pharmacokinetics and Brain Target Occupancy , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[31] S. Kapur,et al. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. , 2009, Current pharmaceutical design.
[32] R. P. Maguire,et al. Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[33] S. Kapur,et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. , 2000, The American journal of psychiatry.
[34] P. Matthews,et al. Towards molecular imaging of multiple sclerosis , 2011, Multiple sclerosis.
[35] Heinz-Peter Schlemmer,et al. PET/MRI: Paving the Way for the Next Generation of Clinical Multimodality Imaging Applications , 2010, Journal of Nuclear Medicine.
[36] R L Wahl,et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] R. Pérez-Tomás,et al. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. , 2006, Current medicinal chemistry.
[38] M. Ranson,et al. Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study , 2010, Clinical Cancer Research.
[39] A. D. Van den Abbeele,et al. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). , 2002, European journal of cancer.
[40] P A Sargent,et al. Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. , 1996, European journal of pharmacology.
[41] Michael Brady,et al. A Biomathematical Modeling Approach to Central Nervous System Radioligand Discovery and Development , 2009, Journal of Nuclear Medicine.
[42] E. Rabiner,et al. PET studies in drug development: Methodological considerations. , 2005, Drug discovery today. Technologies.